Dysregulated CARD11 signaling in the development of diffuse large B cell lymphoma

Aalipour A. and Advani R.H. 2014. Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: Focus on ibrutinib. Ther. Adv. Hematol. 5(4): 121–133.

Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., Nakanishi K., and Akira S. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity, 9(1): 143–150.

Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson J. Jr., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., and Staudt L.M. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403(6769): 503–511.

Arjunaraja S., Nosé B.D., Sukumar G., Lott N.M., Dalgard C.L., and Snow A.L. 2017. Intrinsic plasma cell differentiation defects in B cell expansion with NF-κB and T cell anergy patient B cells. Front. Immunol. 8: 913.

Bedsaul J.R., Carter N.M., Deibel K.E., Hutcherson S.M., Jones T.A., Wang Z., Yang C., Yang Y.K., and Pomerantz J.L. 2018. Mechanisms of regulated and dysregulated CARD11 signaling in adaptive immunity and disease. Front. Immunol. 9: 2105.

Beg A.A., Ruben S.M., Scheinman R.I., Haskill S., Rosen C.A., and Baldwin A.S. Jr. 1992. I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: A mechanism for cytoplasmic retention. Genes Dev. 6(10): 1899–1913.

Blonska M., Pappu B.P., Matsumoto R., Li H., Su B., Wang D., and Lin X. 2007. The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling pathway. Immunity, 26(1): 55–66.

Brummelkamp T.R., Nijman S.M., Dirac A.M., and Bernards R. 2003. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature, 424(6950): 797–801.

Buchbinder D., Stinson J.R., Nugent D.J., Heurtier L., Suarez F., Sukumar G., Dalgard C.L., Masson C., Parisot M., Zhang Y., Matthews H.F., Su H.C., Durandy A., Fischer A., Kracker S., and Snow A.L. 2015. Mild B-cell lymphocytosis in patients with a CARD11 C49Y mutation. J. Allergy Clin. Immunol. 136(3): 819–821.e1.

Burgering B.M.T. 2008. A brief introduction to FOXOlogy. Oncogene, 27(16): 2258–2262.

Chan W., Schaffer T.B., and Pomerantz J.L. 2013. A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival. Mol. Cell. Biol. 33(2): 429–443.

Che T., You Y., Wang D., Tanner M.J., Dixit V.M., and Lin X. 2004. MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-κB activation. J. Biol. Chem. 279(16): 15870–15876.

Chen Z.J. 2012. Ubiquitination in signaling to and activation of IKK. Immunol. Rev. 246(1): 95–106.

Coiffier B. and Sarkozy C. 2016. Diffuse large B-cell lymphoma: R-CHOP failure—What to do? Hematology, 2016(1): 366–378.

Compagno M., Lim W.K., Grunn A., Nandula S.V., Brahmachary M., Shen Q., Bertoni F., Ponzoni M., Scandurra M., Califano A., Bhagat G., Chadburn A., Dalla-Favera R., and Pasqualucci L. 2009. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature, 459(7247): 717–721.

Coornaert B., Baens M., Heyninck K., Bekaert T., Haegman M., Staal J., Sun L., Chen Z.J., Marynen P., and Beyaert R. 2008. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-κB inhibitor A20. Nat. Immunol. 9(3): 263–271.

Cui J., Wang Q., Wang J., Lv M., Zhu N., Li Y., Feng J., Shen B., and Zhang J. 2009. Basal c-Jun NH₂-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells. Mol. Cancer Ther. 8(12): 3214–3222.

da Silva Almeida A.C., Abate F., Khiabanian H., Martinez-Escala E., Guitart J., Tensen C.P., Vermeer M.H., Rabadan R., Ferrando A., and Palomero T. 2015. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat. Genet. 47(12): 1465–1470.

Davis R.E., Brown K.D., Siebenlist U., and Staudt L.M. 2001. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194(12): 1861–1874.

Demo S.D., Kirk C.J., Aujay M.A., Buchholz T.J., Dajee M., Ho M.N., Jiang J., Laidig G.J., Lewis E.R., Parlati F., Shenk K.D., Smyth M.S., Sun C.M., Vallone M.K., Woo T.M., Molineaux C.J., and Bennett M.K. 2007. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67(13): 6383–6391.

Dominguez-Sola D., Kung J., Holmes A.B., Wells V.A., Mo T., Basso K., and Dalla-Favera R. 2015. The FOXO1 transcription factor instructs the germinal center dark zone program. Immunity, 43(6): 1064–1074.

Don A.S. and Zheng X.F. 2010. Recent clinical trials of mTOR-targeted cancer therapies. Rev. Recent Clin. Trials, 6(1): 24–35.

Dunleavy K., Pittaluga S., Czuczman M.S., Dave S.S., Wright G., Grant N., Shovlin M., Jaffe E.S., Janik J.E., Staudt L.M., and Wilson W.H. 2009. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood, 113(24): 6069–6076.

Düwel M., Welteke V., Oeckinghaus A., Baens M., Kloo B., Ferch U., Darnay B.G., Ruland J., Marynen P., and Krappmann D. 2009. A20 Negatively regulates T cell receptor signaling to NF-κB by cleaving Malt1 ubiquitin chains. J. Immunol. 182(12): 7718–7728.

Eferl R. and Wagner E.F. 2003. AP-1: A double-edged sword in tumorigenesis. Nat. Rev. Cancer, 3(11): 859–868.

Ezell S.A., Mayo M., Bihani T., Tepsuporn S., Wang S., Passino M., Grosskurth S.E., Collins M., Parmentier J., Reimer C., and Byth K.F. 2014. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma. Oncotarget, 5(13): 4990–5001.

Ferch U., Kloo B., Gewies A., Pfänder V., Düwel M., Peschel C., Krappmann D., and Ruland J. 2009. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 206(11): 2313–2320.

Fisher S.G. and Fisher R.I. 2004. The epidemiology of non-Hodgkin’s lymphoma. Oncogene, 23(38): 6524–6534.

Fontan L., Yang C., Kabaleeswaran V., Volpon L., Osborne M.J., Beltran E., Garcia M., Cerchietti L., Shaknovich R., Yang S.N., Fang F., Gascoyne R.D., Martinez-Climent J.A., Glickman J.F., Borden K., Wu H., and Melnick A. 2012. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell, 22(6): 812–824.

Gu J.J., Hernandez-Ilizaliturri F.J., Kaufman G.P., Czuczman N.M., Mavis C., Skitzki J.J., and Czuczman M.S. 2013. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br. J. Haematol. 162(5): 657–669.

Hailfinger S., Lenz G., Ngo V., Posvitz-Fejfar A., Rebeaud F., Guzzardi M., Penas E.M., Dierlamm J., Chan W.C., Staudt L.M., and Thome M. 2009. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 106(47): 19946–19951.

Hamilton K.S., Phong B., Corey C., Cheng J., Gorentla B., Zhong X., Shiva S., and Kane L.P. 2014. T cell receptor–dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10. Sci. Signal. 7(329): ra55.

Jattani R.P., Tritapoe J.M., and Pomerantz J.L. 2016a. Cooperative control of caspase recruitment domain-containing protein 11 (CARD11) signaling by an unusual array of redundant repressive elements. J. Biol. Chem. 291(16): 8324–8336.

Jattani R.P., Tritapoe J.M., and Pomerantz J.L. 2016b. Intramolecular interactions and regulation of cofactor binding by the four repressive elements in the caspase recruitment domain-containing protein 11 (CARD11) inhibitory domain. J. Biol. Chem. 291(16): 8338–8348.

Jeelall Y.S., Wang J.Q., Law H.D., Domaschenz H., Fung H.K., Kallies A., Nutt S.L., Goodnow C.C., and Horikawa K. 2012. Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production. J. Exp. Med. 209(11): 1907–1917.

Jin Z., Qing K., Ouyang Y., Liu Z., Wang W., Li X., Xu Z., and Li J. 2016. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma. J. Exp. Clin. Cancer Res. 35: 52.

Juilland M., Gonzalez M., Erdmann T., Banz Y., Jevnikar Z., Hailfinger S., Tzankov A., Grau M., Lenz G., Novak U., and Thome M. 2016. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. Blood, 127(14): 1780–1789.

Kataoka K., Nagata Y., Kitanaka A., Shiraishi Y., Shimamura T., Yasunaga J., Totoki Y., Chiba K., Sato-Otsubo A., Nagae G., Ishii R., Muto S., Kotani S., Watatani Y., Takeda J., Sanada M., Tanaka H., Suzuki H., Sato Y., Shiozawa Y., Yoshizato T., Yoshida K., Makishima H., Iwanaga M., Ma G., Nosaka K., Hishizawa M., Itonaga H., Imaizumi Y., Munakata W., Ogasawara H., Sato T., Sasai K., Muramoto K., Penova M., Kawaguchi T., Nakamura H., Hama N., Shide K., Kubuki Y., Hidaka T., Kameda T., Nakamaki T., Ishiyama K., Miyawaki S., Yoon S.S., Tobinai K., Miyazaki Y., Takaori-Kondo A., Matsuda F., Takeuchi K., Nureki O., Aburatani H., Watanabe T., Shibata T., Matsuoka M., Miyano S., Shimoda K., and Ogawa S. 2015. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat. Genet. 47(11): 1304–1315.

Kato M., Sanada M., Kato I., Sato Y., Takita J., Takeuchi K., Niwa A., Chen Y., Nakazaki K., Nomoto J., Asakura Y., Muto S., Tamura A., Iio M., Akatsuka Y., Hayashi Y., Mori H., Igarashi T., Kurokawa M., Chiba S., Mori S., Ishikawa Y., Okamoto K., Tobinai K., Nakagama H., Nakahata T., Yoshino T., Kobayashi Y., and Ogawa S. 2009. Frequent inactivation of A20 in B-cell lymphomas. Nature, 459(7247): 712–716.

Kawai T., Adachi O., Ogawa T., Takeda K., and Akira S. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity, 11(1): 115–122.

Knies N., Alankus B., Weilemann A., Tzankov A., Brunner K., Ruff T., Kremer M., Keller U.B., Lenz G., and Ruland J. 2015. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation. Proc. Natl. Acad. Sci. U.S.A. 112(52): E7230–E7238.

Kovalenko A., Chable-Bessia C., Cantarella G., Israël A., Wallach D., and Courtois G. 2003. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature, 424(6950): 801–805.

Lamason R.L., McCully R.R., Lew S.M., and Pomerantz J.L. 2010. Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain. Biochemistry, 49(38): 8240–8250.

Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., Dave S.S., Zhao H., Xu W., Rosenwald A., Ott G., Muller-Hermelink H.K., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I., Chan W.C., and Staudt L.M. 2008. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science, 319(5870): 1676–1679.

Lu H.Y., Bauman B.M., Arjunaraja S., Dorjbal B., Milner J.D., Snow A.L., and Turvey S.E. 2018. The CBM-opathies—A rapidly expanding spectrum of human inborn errors of immunity caused by mutations in the CARD11-BCL10-MALT1 complex. Front. Immunol. 9: 2078.

Matsumoto R., Wang D., Blonska M., Li H., Kobayashi M., Pappu B., Chen Y., Wang D., and Lin X. 2005. Phosphorylation of CARMA1 plays a critical role in T cell receptor-mediated NF-κB activation. Immunity, 23(6): 575–585.

Maul R.W. and Gearhart P.J. 2010. Controlling somatic hypermutation in immunoglobulin variable and switch regions. Immunol. Res. 47(1–3): 113–122.

McConkey D.J. and Zhu K. 2008. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updates, 11(4–5): 164–179.

Medema R.H., Kops G.J., Bos J.L., and Burgering B.M. 2000. AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27^kip1. Nature, 404(6779): 782–787.

Merli M., Ferrario A., Maffioli M., Arcaini L., and Passamonti F. 2015. Everolimus in diffuse large B-cell lymphomas. Future Oncol. 11(3): 373–383.

Nagel D., Spranger S., Vincendeau M., Grau M., Raffegerst S., Kloo B., Hlahla D., Neuenschwander M., Peter von Kries J., Hadian K., Dörken B., Lenz P., Lenz G., Schendel D.J., and Krappmann D. 2012. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell, 22(6): 825–837.

Nagel D., Bognar M., Eitelhuber A.C., Kutzner K., Vincendeau M., and Krappmann D. 2015. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma. Oncotarget, 6(39): 42232–42242.

Nakaya M., Xiao Y., Zhou X., Chang J.H., Chang M., Cheng X., Blonska M., Lin X., and Sun S.C. 2014. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity, 40(5): 692–705.

Ngo V.N., Davis R.E., Lamy L., Yu X., Zhao H., Lenz G., Lam L.T., Dave S., Yang L., Powell J., and Staudt L.M. 2006. A loss-of-function RNA interference screen for molecular targets in cancer. Nature, 441(1): 106–110.

Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., Kohlhammer H., Xu W., Yang Y., Zhao H., Shaffer A.L., Romesser P., Wright G., Powell J., Rosenwald A., Muller-Hermelink H.K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., and Staudt L.M. 2011. Oncogenically active MYD88 mutations in human lymphoma. Nature, 470(7332): 115–119.

Oeckinghaus A., Wegener E., Welteke V., Ferch U., Arslan S.C., Ruland J., Scheidereit C., and Krappmann D. 2007. Malt1 ubiquitination triggers NF-κB signaling upon T-cell activation. EMBO J. 26(22): 4634–4645.

Pedersen S.M., Chan W., Jattani R.P., Mackie d.S., and Pomerantz J.L. 2016. Negative regulation of CARD11 signaling and lymphoma cell survival by the E3 ubiquitin ligase RNF181. Mol. Cell. Biol. 36(5): 794–808.

Phelan J.D., Young R.M., Webster D.E., Roulland S., Wright G.W., Kasbekar M., Shaffer A.L. III, Ceribelli M., Wang J.Q., Schmitz R., Nakagawa M., Bachy E., Huang D.W., Ji Y., Chen L., Yang Y., Zhao H., Yu X., Xu W., Palisoc M.M., Valadez R.R., Davies-Hill T., Wilson W.H., Chan W.C., Jaffe E.S., Gascoyne R.D., Campo E., Rosenwald A., Ott G., Delabie J., Rimsza L.M., Rodriguez F.J., Estephan F., Holdhoff M., Kruhlak M.J., Hewitt S.M., Thomas C.J., Pittaluga S., Oellerich T., and Staudt L.M. 2018. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature, 560(7718): 387–391.

Reddy A., Zhang J., Davis N.S., Moffitt A.B., Love C.L., Waldrop A., Leppa S., Pasanen A., Meriranta L., Karjalainen-Lindsberg M.L., Nørgaard P., Pedersen M., Gang A.O., Høgdall E., Heavican T.B., Lone W., Iqbal J., Qin Q., Li G., Kim S.Y., Healy J., Richards K.L., Fedoriw Y., Bernal-Mizrachi L., Koff J.L., Staton A.D., Flowers C.R., Paltiel O., Goldschmidt N., Calaminici M., Clear A., Gribben J., Nguyen E., Czader M.B., Ondrejka S.L., Collie A., Hsi E.D., Tse E., Au-Yeung R.K.H., Kwong Y.L., Srivastava G., Choi W.W.L., Evens A.M., Pilichowska M., Sengar M., Reddy N., Li S., Chadburn A., Gordon L.I., Jaffe E.S., Levy S., Rempel R., Tzeng T., Happ L.E., Dave T., Rajagopalan D., Datta J, Dunson D.B., and Dave S.S. 2017. Genetic and functional drivers of diffuse large B cell lymphoma. Cell, 171(2): 481–494.e15.

Reiley W.W., Jin W., Lee A.J., Wright A., Wu X., Tewalt E.F., Leonard T.O., Norbury C.C., Fitzpatrick L., Zhang M., and Sun S.C. 2007. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 204(6): 1475–1485.

Rovira J., Valera A., Colomo L., Setoain X., Rodríguez S., Martínez-Trillos A., Giné E., Dlouhy I., Magnano L., Gaya A., Martínez D., Martínez A., Campo E., and López-Guillermo A. 2015. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann. Hematol. 94(5): 803–812.

Ruland J., Duncan G.S., Elia A., del Barco Barrantes I., Nguyen L., Plyte S., Millar D.G., Bouchard D., Wakeham A., Ohashi P.S., and Mak T.W. 2001. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure. Cell, 104(1): 33–42.

Sander S., Chu V.T., Yasuda T., Franklin A., Graf R., Calado D.P., Li S., Imami K., Selbach M., Di Virgilio M., Bullinger L., and Rajewsky K. 2015. PI3 kinase and FOXO1 transcription factor activity differentially control B cells in the germinal center light and dark zones. Immunity, 43(6): 1075–1086.

Schmidt M., Fernandez de Mattos S., van der Horst A., Klompmaker R., Kops G.J., Lam E.W., Burgering B.M., and Medema R.H. 2002. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol. Cell. Biol. 22(22): 7842–7852.

Sebestyén A., Sticz T.B., Márk A., Hajdu M., Timár B., Nemes K., Nagy N., Váradi Z., and Kopper L. 2012. Activity and complexes of mTOR in diffuse large B-cell lymphomas—A tissue microarray study. Mod. Pathol. 25(12): 1623–1628.

Shembade N., Ma A., and Harhaj E.W. 2010. Inhibition of NF-κB signaling by A20 through discruption of ubiquitin enzyme complexes. Science, 327(5969): 1135–1139.

Shinohara H., Maeda S., Watarai H., and Kurosaki T. 2007. IκB kinase β-induced phosphorylation of CARMA1 contributes to CARMA1-Bcl10-MALT1 complex formation in B cells. J. Exp. Med. 204(13): 3285–3293.

Snow A.L., Xiao W., Stinson J.R., Lu W., Chaigne-Delalande B., Zheng L., Pittaluga S., Matthews H.F., Schmitz R., Jhavar S., Kuchen S., Kardava L., Wang W., Lamborn I.T., Jing H., Raffeld M., Moir S., Fleisher T.A., Staudt L.M., Su H.C., and Lenardo M.J. 2012. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. J. Exp. Med. 209(12): 2247–2261.

Sommer K., Guo B., Pomerantz J.L., Bandaranayake A.D., Moreno-García M.E., Ovechkina Y.L., and Rawlings D.J. 2005. Phosphorylation of the CARMA1 linker controls NF-κB activation. Immunity, 23(6): 561–574.

Srinivasula S.M. and Ashwell J.D. 2011. A20: More than one way to skin a cat. Mol. Cell, 44(4): 511–512.

Staal J., Driege Y., Bekaert T., Demeyer A., Muyllaert D., Van Damme P., Gevaert K., and Beyaert R. 2011. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J. 30(9): 1742–1752.

Sun L., Deng L., Ea C.K., Xia Z.P., and Chen Z.J. 2004. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell, 14(3): 289–301.

Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H., Ashworth A., and Mosialos G. 2003. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature, 424(6950): 793–796.

Vallois D., Dobay M.P., Morin R.D., Lemonnier F., Missiaglia E., Juilland M., Iwaszkiewicz J., Fataccioli V., Bisig B., Roberti A., Grewal J., Bruneau J., Fabiani B., Martin A., Bonnet C., Michielin O., Jais J.P., Figeac M., Bernard O.A., Delorenzi M., Haioun C., Tournilhac O., Thome M., Gascoyne R.D., Gaulard P., and de Leval L. 2016. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood, 128(11): 1490–1502.

Victora G.D., Dominguez-Sola D., Holmes A.B., Deroubaix S., Dalla-Favera R., and Nussenzweig M.C. 2012. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood, 120(11): 2240–2248.

Wang L., Ni X., Covington K.R., Yang B.Y., Shiu J., Zhang X., Xi L., Meng Q., Langridge T., Drummond J., Donehower L.A., Doddapaneni H., Muzny D.M., Gibbs R.A., Wheeler D.A., and Duvic M. 2015. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat. Genet. 47(12): 1426–1434.

Wei Z., Zhang Y., Chen J., Hu Y., Jia P., Wang X., Zhao Q., Deng Y., Li N., Zang Y., Qin J., Wang X., and Lu W. 2019. Pathogenic CARD11 mutations affect B cell development and differentiation through a noncanonical pathway. Sci. Immunol. 4(41): eaaw5618.

Wilson W.H., Young R.M., Schmitz R., Yang Y., Pittaluga S., Wright G., Lih C.J., Williams P.M., Shaffer A.L., Gerecitano J., de Vos S., Goy A., Kenkre V.P., Barr P.M., Blum K.A., Shustov A., Advani R., Fowler N.H., Vose J.M., Elstrom R.L., Habermann T.M., Barrientos J.C., McGreivy J., Fardis M., Chang B.Y., Clow F., Munneke B., Moussa D., Beaupre D.M., and Staudt L.M. 2015. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 21(8): 922–926.

Wray-Dutra M.N., Chawla R., Thomas K.R., Seymour B.J., Arkatkar T., Sommer K.M., Khim S., Trapnell C., James R.G., and Rawlings D.J. 2018. Activated CARD11 accelerates germinal center kinetics, promoting mTORC1 and terminal differentiation. J. Exp. Med. 215(9): 2445–2461.

Wu Q., Wu W., Jacevic V., Franca T.C.C., Wang X., and Kuca K. 2020. Selective inhibitors for JNK signalling: A potential targeted therapy in cancer. J. Enzyme Inhib. Med. Chem. 35(1): 574–583.

Xu X. 2019. BTK inhibitors induce ABC-DLBCL cell apoptosis by inhibiting CYLD phosphorylation. Blood, 134(Suppl. 1): 5046.

Yang C., David L., Qiao Q., Damko E., and Wu H. 2014. The CBM signalosome: Potential therapeutic target for aggressive lymphoma? Cytokine Growth Factor Rev. 25(2): 175–183.

Yang J., Nie J., Ma X., Wei Y., Peng Y., and Wei X. 2019. Targeting PI3K in cancer: Mechanisms and advances in clinical trials. Mol. Cancer, 18(1): 26.

Yang W.L., Wang J., Chan C.H., Lee S.W., Campos A.D., Lamothe B., Hur L., Grabiner B.C., Lin X., Darnay B.G., and Lin H.K. 2009. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science, 325: 1134–1138.

Yang Y., Schmitz R., Mitala J., Whiting A., Xiao W., Ceribelli M., Wright G.W., Zhao H., Yang Y., Xu W., Rosenwald A., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Wiestner A., Kruhlak M.J., Iwai K., Bernal F., and Staudt L.M. 2014. Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov. 4(4): 480–493.

Yang Y.K., Yang C., Chan W., Wang Z., Deibel K.E., and Pomerantz J.L. 2016. Molecular determinants of scaffold-induced linear ubiquitinylation of B cell lymphoma/leukemia 10 (Bcl10) during T cell receptor and oncogenic caspase recruitment domain-containing protein 11 (CARD11) signaling. J. Biol. Chem. 291(50): 25921–25936.

Yoshida H., Jono H., Kai H., and Li J.D. 2005. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7. J. Biol. Chem. 280(49): 41111–41121.

Yusuf I., Zhu X., Kharas M.G., Chen J., and Fruman D.A. 2004. Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. Blood, 104(3): 784–787.